Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia

Few reports assess prognosis during follow-up of patients with symptomatic Waldenström macroglobulinemia (WM). In 121 WM patients treated between 1993 and 2016, we analyzed the prognostic role during the clinical course of the initial International Prognostic Scoring System for WM (IPSSWM). Then, we...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Guidez, Stephanie, Labreuche, Julien, Drumez, Elodie, Ysebaert, Loic, Bakala, Jana, Delette, Caroline, Hivert, Bénédicte, Protin, Caroline, Declercq, Hervé, Verlay, Mélanie, Marolleau, Jean Pierre, Duhamel, Alain, Morel, Pierre
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2018
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6258926/
https://ncbi.nlm.nih.gov/pubmed/30455359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018021287
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak